赛升药业
(300485)
| 流通市值：34.83亿 | | | 总市值：61.27亿 |
| 流通股本：2.74亿 | | | 总股本：4.82亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 196,801,173.6 | 92,536,534.42 | 416,481,789.63 | 322,881,323.81 |
| 营业收入 | 196,801,173.6 | 92,536,534.42 | 416,481,789.63 | 322,881,323.81 |
| 二、营业总成本 | 190,738,723.09 | 90,214,129.14 | 391,077,044.74 | 304,126,046.59 |
| 营业成本 | 69,310,742.75 | 34,961,556.51 | 140,431,159.79 | 110,215,987.39 |
| 税金及附加 | 4,789,093.69 | 1,286,380.7 | 7,002,149.36 | 4,268,704.19 |
| 销售费用 | 65,515,772.16 | 29,937,487.7 | 141,598,934.14 | 112,604,115.62 |
| 管理费用 | 23,870,571.07 | 12,185,708.62 | 57,518,499.61 | 38,394,297.75 |
| 研发费用 | 27,331,613.64 | 11,888,734.88 | 46,215,169.74 | 40,216,529.84 |
| 财务费用 | -79,070.22 | -45,739.27 | -1,688,867.9 | -1,573,588.2 |
| 其中:利息收入 | 93,453.09 | 57,234.48 | 1,705,616.72 | 1,584,599.67 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 38,542,068.26 | 30,376,664.04 | -56,509,203.23 | -86,936,601.14 |
| 加:投资收益 | 7,452,845.57 | 16,177,555.17 | -51,620,778.39 | -54,860,250.85 |
| 资产处置收益 | 111,881.57 | - | - | - |
| 资产减值损失(新) | - | - | -2,795,384.68 | - |
| 信用减值损失(新) | -1,143,047.16 | -1,753,407.46 | 1,471,147.75 | 601,242.4 |
| 其他收益 | 614,110.76 | 252,178.11 | 1,075,604.29 | 1,174,745.88 |
| 四、营业利润 | 51,640,309.51 | 47,375,395.14 | -82,973,869.37 | -121,265,586.49 |
| 加:营业外收入 | 17,277.35 | 129,058.92 | 370,316.34 | 330,630.17 |
| 减:营业外支出 | - | - | 962,441.64 | 566,767.53 |
| 五、利润总额 | 51,657,586.86 | 47,504,454.06 | -83,565,994.67 | -121,501,723.85 |
| 减:所得税费用 | 5,902,576.36 | 8,559,522.12 | -6,691,856.98 | -19,296,409.3 |
| 六、净利润 | 45,755,010.5 | 38,944,931.94 | -76,874,137.69 | -102,205,314.55 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 45,755,010.5 | 38,944,931.94 | -76,874,137.69 | -102,205,314.55 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 47,786,232.79 | 39,970,025.94 | -68,853,096.03 | -98,198,160.93 |
| 少数股东损益 | -2,031,222.29 | -1,025,094 | -8,021,041.66 | -4,007,153.62 |
| 扣除非经常损益后的净利润 | 8,643,625.9 | 1,189,981.78 | 11,760,028.82 | 17,547,483.04 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.1 | 0.08 | -0.14 | -0.2 |
| (二)稀释每股收益 | 0.1 | 0.08 | -0.14 | -0.2 |
| 八、其他综合收益 | -153,451.77 | -52,523.3 | 537,717.47 | -382,426.79 |
| 归属于母公司股东的其他综合收益 | -153,451.77 | -52,523.3 | 537,717.47 | -382,426.79 |
| 九、综合收益总额 | 45,601,558.73 | 38,892,408.64 | -76,336,420.22 | -102,587,741.34 |
| 归属于母公司股东的综合收益总额 | 47,632,781.02 | 39,917,502.64 | -68,315,378.56 | -98,580,587.72 |
| 归属于少数股东的综合收益总额 | -2,031,222.29 | -1,025,094 | -8,021,041.66 | -4,007,153.62 |
| 公告日期 | 2025-08-22 | 2025-04-24 | 2025-03-29 | 2024-10-25 |
| 审计意见(境内) | | | 标准无保留意见 | |